drugset / Trial / NCT05672537
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
Timeline
- Start
- 2023-01-20
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |